Blood and plasma products and vaccines maker CSL (CSL) reported its half year numbers today
CommSec
Online Stockbroker
Blood and plasma products and vaccines maker CSL (CSL) reported its half year numbers today. The CSL Group reported a 3.7% rise in sales with total revenue (includes royalties) increasing by 4.8% to US$2.691 billion. The company did take a hit in this result due to the one-off US antitrust class action litigation settlement of US$64 million. CSL will pay a half year dividend of US$0.53. The said it expects FY14 after tax profit growth of around 7% and CSL will continue its current A$950 million share buyback that is now 22% completed. Watch full report here:
Never miss an update
Enjoy this wire? Hit the ‘like’ button to let us know.
Stay up to date with my current content by
following me below and you’ll be notified every time I post a wire
CommSec is Australia's leading online broker. CommSec has been committed to providing the best in online trading since 1995. CommSec helps make informed investment decisions with comprehensive market research, free live pricing and powerful trading tools including alerts, conditional orders, stock screeners and comparison charts.
CommSec
Online Stockbroker
Online Stockbroker
CommSec is Australia's leading online broker. CommSec has been committed to providing the best in online trading since 1995. CommSec helps make informed investment decisions with comprehensive market research, free live pricing and powerful...
Expertise
No areas of expertise
CommSec
Online Stockbroker
Online Stockbroker
CommSec is Australia's leading online broker. CommSec has been committed to providing the best in online trading since 1995. CommSec helps make informed investment decisions with comprehensive market research, free live pricing and powerful...
Expertise
No areas of expertise
Comments
Comments
Sign In or Join Free to comment
most popular
Equities
This recently triggered market signal has never failed to predict gains
Ophir Asset Management